Mediators of Inflammation

Mediators of Inflammation / 2013 / Article
Special Issue

Inflammation in the Disease: Mechanism and Therapies

View this Special Issue

Research Article | Open Access

Volume 2013 |Article ID 813091 | 7 pages | https://doi.org/10.1155/2013/813091

Cigarette Smoke Suppresses the Surface Expression of c-kit and FcεRI on Mast Cells

Academic Editor: Fábio Santos Lira
Received18 Oct 2012
Revised01 Jan 2013
Accepted02 Jan 2013
Published12 Feb 2013

Abstract

Chronic obstructive pulmonary disease (COPD) is a multicomponent disease characterized by emphysema and/or chronic bronchitis. COPD is mostly associated with cigarette smoking. Cigarette smoke contains over 4,700 chemical compounds, including free radicals and LPS (a Toll-Like Receptor 4 agonist) at concentrations which may contribute to the pathogenesis of diseases like COPD. We have previously shown that short-term exposure to cigarette smoke medium (CSM) can stimulate several inflammatory cells via TLR4 and that CSM reduces the degranulation of bone-marrow-derived mast cells (BMMCs). In the current study, the effect of CSM on mast cells maturation and function was investigated. Coculturing of BMMC with CSM during the development of bone marrow progenitor cells suppressed the granularity and the surface expression of c-kit and FcεRI receptors. Stimulation with IgE/antigen resulted in decreased degranulation and release of Th1 and Th2 cytokines. The effects of CSM exposure could not be mimicked by the addition of LPS to the culture medium. In conclusion, this study shows that CSM may affect mast cell development and subsequent response to allergic activation in a TLR4-independent manner.

1. Introduction

The incidence of chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma is increasing dramatically and currently affect the lives of approximately 300 and 200 million people, respectively, worldwide [1, 2]. COPD is characterized by a complex interaction between inflammatory and structural cells, all of which have the capacity to release multiple inflammatory mediators [3]. Cigarette smoke (CS) is the major player in the pathogenesis of COPD [3]. Exposure to CS activates an inflammatory cascade in the airways resulting in the production of a number of potent cytokines and chemokines with accompanying damage to the lung epithelium, increased permeability, and recruitment of macrophages and neutrophils [4]. CS contains high levels of reactive oxygen species [5] and LPS [6, 7]. LPS is a strong Toll-Like Receptor (TLR) 4 agonist [8]. TLRs are an evolutionarily conserved family of cell surface molecules which participate in innate immune response [9, 10]. The effects of smoking on inflammatory cell maturation and differentiation have not been well described. Upon encountering pathogens and/or proinflammatory mediators, cells undergo a transformation process termed “maturation,” which, for example, enhances dendritic cell (DC) Ag-presenting capacity or ability to release inflammatory cytokines. The role of TLRs in maturation and development of DCs [11] and B cells [12] has been extensively described. In this regard, it has been reported that CS exposure leads to (a) decreased sputum mature DCs in healthy smokers and patients with COPD [13], (b) impaired DC maturation and T-cell proliferation in thoracic lymph nodes of mice [14] and (c) suppressed generation of IL-12 and IL-23 from DCs mediated through ERK-dependent pathways [15].

Parental smoking during childhood and personal cigarette smoking in teenage and early adult life are associated with a lower risk of allergic sensitization in those with a family history of atopy. The underlying mechanisms for this association remain to be determined, but the findings are consistent with the hypothesis that the immune-suppressant effects of CS protect against atopy [16]. So far few studies have reported on the role of mast cells in human smokers and in animal models of emphysema. Mast cells normally reside close to epithelia, blood vessels, nerves, smooth muscle cells, and mucus-producing glands [17]. Mast cells play a crucial role in allergic reactions [18]. Interestingly, emerging evidence also suggests a role of mast cells in the pathogenesis of emphysema [19, 20]. Kalenderian et al. [19, 20] found that the levels of mast cell mediators, such as histamine and tryptase, are considerably elevated in BALF from smokers. The importance of mast cells is further supported by the fact that mast cell tryptase activity is correlated with the severity of COPD [21], and in COPD patients an accumulation of mast cells in the airways has been observed [22]. Mast cells located here could be exposed to inhaled environmental challenges, and mast cell activation results in the coordinated release of proinflammatory mediators into the surrounding tissue; activation of this cell type may result in pathology associated with chronic inflammatory stimuli [23, 24]. Mast cells play a crucial role in acute and allergic inflammation and have FcεRI on their surface [24]. Cross-linking of surface IgE molecules results in exocytosis of preformed mediators such as amines and proteases, as well as the release of newly generated mediators including leukotrienes, prostaglandins, and a variety of cytokines such as Th1 (TNF- , IL-6) or Th2 cytokines (IL-13, IL-4, IL-5) [24].

Previously, we showed that CSM (without IgE/Ag activation) does not trigger degranulation of bone marrow-derived mast cells (BMMCs) but does induce the release of chemokines [2]. In addition, CSM exposure suppresses IgE-mediated mast cell degranulation and cytokine release but had no effect on leukotriene release. This suggests that exposure to CSM may lead to a reduced allergic activation of mast cells without affecting their response to other stimuli [25]. In contrast, CS exposure in vivo enhanced OVA-specific IgE levels, Penh values, and recruitment of inflammatory cells including mast cells in OVA-exposed allergic mice [26].

In the current study, we investigated the effect of CSM exposure on the mast cell development from bone marrow progenitor cells.

2. Materials and Methods

2.1. Reagents

Recombinant mouse IL-3 and SCF (stem cell factor) were purchased from PeproTech (tebu-bio, Heerhugowaard, The Netherlands). LPS (Escherichia coli 055.B5) was purchased from Sigma (Sigma-Aldrich, Zwijndrecht, The Netherlands). RPMI 1640, Tyrode’s buffer, fetal calf serum, nonessential amino acids were purchased from GIBCO BRL Life Technologies (GIBCO-BRL Invitrogen Corporation, Carlsbad, CA, USA). Penicillin, streptomycin, L-glutamine, sodium pyruvate, and 2-mercaptoethanol were obtained from Sigma-Aldrich.

2.2. Production of Cigarette Smoke Medium (CSM)

Cigarette smoke-conditioned medium (CSM) was produced as described previously [25]. CSM was generated by burning reference cigarettes 2R4F (University of Kentucky, Lexington, KY), using the TE-10z smoking machine (Teague Enterprises, Davis, CA, USA), which is programmed to smoke cigarettes according to the Federal Trade Commission protocol (35 mL puff volume drawn for 2 s, once per minute). Briefly, this machine was used to direct main- and side-stream smoke from one cigarette through a 5 mL culture medium (RPMI without phenol red). Hereafter, absorbance was measured spectrophotometrically, and the media were standardized to the absorbance at 320 nm. The pH of the resultant extract was titrated to pH 7.4 and diluted with medium. This concentration (optical density [OD] = 4.0) was serially diluted with untreated media to 0.75%, 1.5%, and 3% OD and used in the indicated experiments. In preliminary experiments, a CSM concentration of 1.5% was found optimal in the culture experiments.

2.3. Mouse Bone Marrow-Derived Mast Cell (BMMC) Cultures and CSM Treatment

BMMCs were generated from bone marrow of male BALB/cBy mice as described previously [27]. Cells were cultured in RPMI medium supplemented with mitogen-stimulated spleen cell conditioned medium (see below) [28].

Cells were used for the experiments after 3 weeks when a mast cell purity >95% was achieved. Bone marrow cells were cocultured ( /mL) with either 1.5% CSM or LPS (100 ng/mL) during the third week of culture.

2.4. Pokeweed Mitogen-Stimulated Spleen Cell Conditioned Medium (PWM-SCM)

Spleen cells from BALB/c mice (Charles River Breeding Laboratories) were cultured at a density of  cells/mL in RPMI 1640 medium containing 4 mM L-glutamine,  M 2-mercaptoethanol, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.1 mM nonessential amino acids (complete RPMI 1640) containing lectin (8 μg/mL) and placed in 75 cm2 tissue culture flasks. The cells were incubated at 37°C in a 5% CO2 humidified atmosphere. After 5–7 days, medium was collected, centrifuged for 15 min at 3200 ×g, filtered through a 0.22 μm Millipore filter, and used as PWM-SCM.

2.5. Toluidine Blue Staining

The granularity of the mast cells was determined by toluidine blue staining [29]. In brief, the cells were cytospun, fixed with Carnoy’s fluid, and then stained by either 2 minutes with acid toluidine blue (pH = 2.7). Cells were examined by light microscopy.

2.6. Mast Cell Degranulation Assay

The degranulation assay was performed as described before [28]. Briefly, approximately 2-  cells from each group were resuspended in culture medium (enriched medium) and incubated with 1 μg/mL anti-DNP-IgE for 2 hr. After that, cells were washed and resuspended at a density of  cells/mL. Cells were aliquoted in 96 well plates ( cells per well) and activated with indicated concentrations of DNP-conjugated ovalbumin (DNP-Ova) for 30 min. After incubation, supernatants were collected. Cells were subsequently lyzed using 0.1% NP-40 (Pierce) in order to quantify the total -hexosaminidase activity present in these cells. Samples were incubated with 4-methylumbelliferyl glucosaminide (4-MUG) (Sigma) in 0.1 M citrate buffer (pH 4.5) for 1 h at 37°C. 4-MUG hydrolysis was determined by fluorimetric measurement (λex: 360 nm, λem: 452 nm) using a Millipore Cytofluor 2350 microplate reader. The percentage of -hexosaminidase released was calculated by determining the ratio of fluorescence supernatant/fluorescence cell lysate corrected for the -hexosaminidase activity present in the supernatant of nonchallenged cells.

2.7. Flow Cytometry Analysis

BMMCs were harvested, and after washing with cold PBS, the cell-surface Fc receptors were blocked with 2.4G2 (PharMingen, San Diego, CA, USA) before staining. We used a PE-conjugated anti-mouse c-kit (PharMingen) to stain c-kit, and mouse FcεRI was stained with an FITC-conjugated anti-mouse FcεRI antibody (PharMingen) and compared with matched isotype control antibodies. The cells were incubated with antibodies in 50 μL of PBS for 1 h at 4°C, washed with PBS, and analyzed on an FACSCantoII flow cytometer (Becton Dickinson, San Jose, CA, USA). Dead cells were gated out when performing the analysis.

2.8. Measurement of Cytokines

Briefly, approximately 1 × 106 cells for each experimental condition were resuspended in culture medium and incubated with 1 μg/mL anti-DNP IgE for 2 hr. After that, cells were washed and resuspended. Cells were aliquoted in 96 well plates (1 × 106 cells/mL) and activated with indicated concentrations of DNP-Ova for 16 h. IL-4, IL-5, IL-6, IL-13, and TNF- concentrations in cell supernatants were quantitated using ELISA (Invitrogen and eBioscience), according to the manufacturer’s instructions.

2.9. Statistical Analysis

Experimental results are expressed as mean ± S.E.M. Results were tested statistically by an unpaired two-tailed Student’s -test or one-way ANOVA, followed by a Newman-Keuls test for comparing all pairs of groups. Analyses were performed by using GraphPad Prism (version 5.04). Results were considered statistically significant when .

3. Results

3.1. CSM Reduced the Granularity of Mast Cells during Culturing

Bone marrow cells were cultured with CSM or LPS during the third week of mast cell development. Cell granularity was analyzed by staining with toluidine blue (Figure 1(a)). Coculturing cells with CSM (1.5%) decreased the granularity of mast cells (Figure 1(b)). LPS (1 μg/mL) did not affect the granularity of cultured mast cells (Figure 1(c)).

3.2. CSM Decreased c-Kit (CD117) and Fc RI Expression on Mast Cells

Mast cell c-kit and FcεRI surface expression was determined after CSM exposure using flow cytometry. Coculture with CSM significantly suppressed the surface expression of c-kit and FcεRI on mast cells (Figure 2: upper and lower panels, control (a), and CSM (b)). In contrast, longterm culture with LPS did not change the surface expression of c-kit and FcεRI (Figure 2(c) upper and lower panels). FACS data of 3 representative experiments were quantified in (d) showing the mean fluorescence intensity (MFI) for each experimental group. Cell viability was not affected by either CSM or LPS treatment (data not shown).

3.3. Long-Term Exposure to CSM Modulates IgE/Ag-Mediated Degranulation and Cytokine Production by Mast Cells

Stimulation with IgE/Ag caused a dose-dependent degranulation of mast cells in the control group (Figure 3). Coculturing mast cells with CSM (1.5%) reduced IgE-mediated degranulation (Figure 3). In contrast, LPS, a TLR4 agonist, did not affect IgE/antigen-induced BMMC degranulation (Figure 3).

CSM significantly suppressed the IgE-receptor mediated production of IL-4, IL-5, IL-6, IL-13, and TNF- by mast cells (Figures 4(a)4(e)). Culturing with LPS did not significantly change IL-4, IL-5, IL-6, IL-13, and TNF- production (Figures 4(a)4(e)).

4. Discussion

In the current studies, we further investigated the effects of CSM on the development and function of primary cultured bone-marrow-derived mast cells. We show that BMMC exposed to CSM during development from progenitor cells inhibited mast cell development as determined by toluidine staining and expression on c-kit and FcεRI. Furthermore, the release of both Th1 and Th2 cytokines in response to FcεRI activation was reduced. Interestingly, the TLR4 agonist LPS did not affect these parameters and even slightly increased IL-4 production.

Mast cells are important in allergic airway diseases, but they have remained poorly studied in nonallergic inflammatory airway diseases like COPD. Mast cells are of particular interest due to their ability to promote airway remodeling and mucus hypersecretion. Clinical data show increased levels of mast cell tryptase and degranulated mast cells in the lavage and bronchial tissue of smokers [3033]. Moreover, CS exposure facilitates allergic sensitization in mice [34].

We have previously reported that short-term exposure of mature mast cells to CSM attenuated their response to allergic stimuli [28]. Kim et al. also showed an inhibitory effect of CSM on mast cell activation which suggests that CS may contribute to the reduced allergic symptoms observed in smokers [26].

Mast cells are functionally dynamic effector cells in innate and adaptive immunity [24]. Two mast cell surface receptors c-Kit and FcεRI mediate activation via innate and adaptive immune mechanisms, respectively [17, 23, 24]. c-Kit is expressed on both mature mast cells and on the earliest mast cell progenitors [35, 36]. c-Kit is expressed both as a soluble form and on the cell membranes [36]. Although c-Kit represents a major growth and differentiation factor for both murine and human mast cells [35, 37] it also promotes c-Kit-dependent mast cell mediator release [38] as well as the release of mast cells mediators via IgE-dependent mechanisms [39]. IgE-dependent allergic diseases are initiated by multivalent binding of allergens to IgE that is bound to FcεRI on mast cells [40]. FcεRI plays a critical role in allergic reactions. It is the major surface receptor through which mast cells direct immunologically specific secretory effects such as the release of preformed cytoplasmic granule-associated mediators and the generation and release of lipid mediators and cytokines [41]. Thus, the suppression of c-Kit and FcεRI on the mast cells by CSM could account for decreased responsiveness of mast cells to IgE/Ag activation. Our study suggests that LPS may not be involved in the mechanism by which CSM affects mast cell maturation and activation.

Mast cells express functional TLRs [42] which may account for the protection conferred by mast cells against bacterial and parasitic infections [43]. Activated mast cells release an array of potent inflammatory mediators by rapid discharge of preformed mediators in granules, the generation of inflammatory lipids from arachidonic acid, and the production of numerous Th2-type cytokines and chemokines [44]. All these responses are evoked by allergens via FcεRI, while stimulation of mast cells via TLR2 and TLR4 receptors results primarily in generation of cytokines such as IL-4, IL-5, IL-6, IL-10, IL-13, and TNF-α [43]. Saluja et al. recently showed that prolonged exposure of mast cells to LPS amplifies FcεRI-mediated degranulation, lipid mediator generation, and cytokine production [45]. This is in contrast to the effects found in this study, where LPS treatment did not increase IgE-mediated mast cell activation. The discrepancy may be due to the different mouse strains used in both studies and the time of treatment during mast cell development.

In conclusion, our study suggests that CSM, independent of TLR4 signaling, suppresses the maturation and function of mast cells. This suppressive effect of cigarette smoke on mast cells may account for the reduced allergic response seen in animal models of cigarette-smoke-induced emphysema [46].

Abbreviations

BMMC:Bone-marrow-derived mast cell
CSM: Cigarette smoke medium
COPD: Chronic obstructive pulmonary disease
FACS:Fluorescence-activated cells sorting
SCF: Stem cell factor
TLR: Toll-like receptor.

References

  1. WHO, Global Surveillance, Prevention Control of Chronic Respiratory: A Comprehensive Approach, World Health Organization, 2007.
  2. P. J. Barnes, “Alveolar macrophages as orchestrators of COPD,” COPD, vol. 1, no. 1, pp. 59–70, 2004. View at: Publisher Site | Google Scholar
  3. P. M. A. Calverley and P. Walker, “Chronic obstructive pulmonary disease,” The Lancet, vol. 362, no. 9389, pp. 1053–1061, 2003. View at: Publisher Site | Google Scholar
  4. P. J. Barnes and R. A. Stockley, “COPD: Current therapeutic interventions and future approaches,” European Respiratory Journal, vol. 25, no. 6, pp. 1084–1106, 2005. View at: Publisher Site | Google Scholar
  5. D. F. Church and W. A. Pryor, “Free-radical chemistry of cigarette smoke and its toxicological implications,” Environmental Health Perspectives, vol. 64, pp. 111–126, 1985. View at: Google Scholar
  6. J. D. Hasday, R. Bascom, J. J. Costa, T. Fitzgerald, and W. Dubin, “Bacterial endotoxin is an active component of cigarette smoke,” Chest, vol. 115, no. 3, pp. 829–835, 1999. View at: Google Scholar
  7. L. Larsson, C. Pehrson, T. Dechen, and M. Crane-Godreau, “Microbiological components in mainstream and sidestream cigarette smoke,” Tobacco Induced Diseases, vol. 10, article 13, 2012. View at: Publisher Site | Google Scholar
  8. T. Kawai and S. Akira, “Toll-like receptors and their crosstalk with other innate receptors in infection and immunity,” Immunity, vol. 34, no. 5, pp. 637–650, 2011. View at: Publisher Site | Google Scholar
  9. B. Keogh and A. E. Parker, “Toll-like receptors as targets for immune disorders,” Trends in Pharmacological Sciences, vol. 32, no. 7, pp. 435–442, 2011. View at: Publisher Site | Google Scholar
  10. R. Medzhitov and C. Janeway, “The toll receptor family and microbial recognition,” Trends in Microbiology, vol. 8, no. 10, pp. 452–456, 2000. View at: Publisher Site | Google Scholar
  11. K. Inaba, M. Inaba, N. Romani et al., “Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor,” Journal of Experimental Medicine, vol. 176, no. 6, pp. 1693–1702, 1992. View at: Publisher Site | Google Scholar
  12. E. A. Hayashi, S. Akira, and A. Nobrega, “Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2,” Journal of Immunology, vol. 174, no. 11, pp. 6639–6647, 2005. View at: Google Scholar
  13. M. Tsoumakidou, I. Bouloukaki, H. Koutala et al., “Decreased sputum mature dendritic cells in healthy smokers and patients with chronic obstructive pulmonary disease,” International Archives of Allergy and Immunology, vol. 150, no. 4, pp. 389–397, 2009. View at: Publisher Site | Google Scholar
  14. C. S. Robbins, F. Franco, M. Mouded, M. Cernadas, and S. D. Shapiro, “Cigarette smoke exposure impairs dendritic cell maturation and T cell proliferation in thoracic lymph nodes of mice,” Journal of Immunology, vol. 180, no. 10, pp. 6623–6628, 2008. View at: Google Scholar
  15. P. R. Kroening, T. W. Barnes, L. Pease, A. Limper, H. Kita, and R. Vassallo, “Cigarette smoke-induced oxidative stress suppresses generation of dendritic cell IL-12 and IL-23 through ERK-dependent pathways,” Journal of Immunology, vol. 181, no. 2, pp. 1536–1547, 2008. View at: Google Scholar
  16. R. J. Hancox, D. Welch, R. Poulton et al., “Cigarette smoking and allergic sensitization: a 32-year population-based cohort study,” Journal of Allergy and Clinical Immunology, vol. 121, no. 1, pp. 38.e3–42.e3, 2008. View at: Publisher Site | Google Scholar
  17. S. J. Galli, “Mast cells and basophils,” Current Opinion in Hematology, vol. 7, no. 1, pp. 32–39, 2000. View at: Publisher Site | Google Scholar
  18. D. D. Metcalfe, D. Baram, and Y. A. Mekori, “Mast cells,” Physiological Reviews, vol. 77, pp. 1033–1079, 1997. View at: Google Scholar
  19. R. Kalenderian, L. Raju, W. Roth, L. B. Schwartz, B. Gruber, and A. Janoff, “Elevated histamine and tryptase levels in smokers' bronchoalveolar lavage fluid. Do lung mast cells contribute to smokers' emphysema?” Chest, vol. 94, no. 1, pp. 119–123, 1988. View at: Google Scholar
  20. V. Bessa, E. Tseliou, P. Bakakos, and S. Loukides, “Noninvasive evaluation of airway inflammation in asthmatic patients who smoke: implications for application in clinical practice,” Annals of Allergy, Asthma and Immunology, vol. 101, no. 3, pp. 226–232, 2008. View at: Google Scholar
  21. X. Zhang, H. Zheng, W. Ma et al., “Tryptase enzyme activity is correlated with severity of chronic obstructive pulmonary disease,” Tohoku Journal of Experimental Medicine, vol. 224, no. 3, pp. 179–187, 2011. View at: Publisher Site | Google Scholar
  22. M. M. E. Gosman, D. S. Postma, J. M. Vonk et al., “Association of mast cells with lung function in chronic obstructive pulmonary disease,” Respiratory Research, vol. 9, article 64, 2008. View at: Publisher Site | Google Scholar
  23. S. J. Galli, J. Wedemeyer, and M. Tsai, “Analyzing the roles of mast cells and basophils in host defense and other biological responses,” International Journal of Hematology, vol. 75, no. 4, pp. 363–369, 2002. View at: Publisher Site | Google Scholar
  24. D. D. Metcalfe, D. Baram, and Y. A. Mekori, “Mast cells,” Physiological Reviews, vol. 77, no. 4, pp. 1033–1079, 1997. View at: Google Scholar
  25. E. Mortaz, F. A. Redegeld, H. Sarir et al., “Cigarette smoke stimulates the production of chemokines in mast cells,” Journal of Leukocyte Biology, vol. 83, no. 3, pp. 575–580, 2008. View at: Publisher Site | Google Scholar
  26. D. Y. Kim, E. Y. Kwon, G. U. Hong, Y. S. Lee, S. H. Lee, and J. Y. Ro, “Cigarette smoke exacerbates mouse allergic asthma through Smad proteins expressed in mast cells,” Respiratory Research, vol. 12, article 49, 2011. View at: Publisher Site | Google Scholar
  27. E. Mortaz, F. A. Redegeld, F. P. Nijkamp, and F. Engels, “Dual effects of acetylsalicylic acid on mast cell degranulation, expression of cyclooxygenase-2 and release of pro-inflammatory cytokines,” Biochemical Pharmacology, vol. 69, no. 7, pp. 1049–1057, 2005. View at: Publisher Site | Google Scholar
  28. E. Mortaz, G. Folkerts, F. Engels, F. P. Nijkamp, and F. A. Redegeld, “Cigarette smoke suppresses in vitro allergic activation of mouse mast cells,” Clinical and Experimental Allergy, vol. 39, no. 5, pp. 679–687, 2009. View at: Publisher Site | Google Scholar
  29. J. S. Marshall, G. P. Ford, and E. B. Bell, “Formalin sensitivity and differential staining of mast cells in human dermis,” British Journal of Dermatology, vol. 117, no. 1, pp. 29–36, 1987. View at: Google Scholar
  30. C. P. Sommerhoff, G. H. Caughey, W. E. Finkbeiner, S. C. Lazarus, C. B. Basbaum, and J. A. Nadel, “Mast cell chymase. A potent secretagogue for airway gland serous cells,” Journal of Immunology, vol. 142, no. 7, pp. 2450–2456, 1989. View at: Google Scholar
  31. H. P. McNeil, R. Adachi, and R. L. Stevens, “Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense,” Journal of Biological Chemistry, vol. 282, no. 29, pp. 20785–20789, 2007. View at: Publisher Site | Google Scholar
  32. T. B. Casale, B. J. Rhodes, A. L. Donnelly, and J. M. Weiler, “Airway responses to metacholine in asymptomatic nonatopic cigarette smokers,” Journal of Applied Physiology, vol. 62, no. 5, pp. 1888–1892, 1987. View at: Google Scholar
  33. W. F. H. Grashoff, J. K. Sont, P. J. Sterk et al., “Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages,” American Journal of Pathology, vol. 151, no. 6, pp. 1785–1790, 1997. View at: Google Scholar
  34. K. B. Moerloose, L. J. Robays, T. Maes, G. G. Brusselle, K. G. Tournoy, and G. F. Joos, “Cigarette smoke exposure facilitates allergic sensitization in mice,” Respiratory Research, vol. 7, article 49, 2006. View at: Publisher Site | Google Scholar
  35. T. Tsujimura, E. Morii, M. Nozaki et al., “Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice,” Blood, vol. 88, no. 4, pp. 1225–1233, 1996. View at: Google Scholar
  36. J. G. Flanagan and P. Leder, “The kit ligand: a cell surface molecule altered in steel mutant fibroblasts,” Cell, vol. 63, no. 1, pp. 185–194, 1990. View at: Publisher Site | Google Scholar
  37. N. S. Yee, H. Langen, and P. Besmer, “Mechanism of kit ligand, phorbol ester, and calcium-induced down- regulation of c-kit receptors in mast cells,” Journal of Biological Chemistry, vol. 268, no. 19, pp. 14189–14201, 1993. View at: Google Scholar
  38. M. Columbo, E. M. Horowitz, L. M. Botana et al., “The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils,” Journal of Immunology, vol. 149, no. 2, pp. 599–608, 1992. View at: Google Scholar
  39. K. Vosseller, G. Stella, N. S. Yee, and P. Besmer, “c-kit receptor signaling through its phosphatidylinositide-3'-kinase- binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling,” Molecular Biology of the Cell, vol. 8, no. 5, pp. 909–922, 1997. View at: Google Scholar
  40. M. A. Beaven and H. Metzger, “Signal transduction by Fc receptors: the FcεRI case,” Immunology Today, vol. 14, no. 5, pp. 222–226, 1993. View at: Google Scholar
  41. D. D. Metcalfe, D. Baram, and Y. A. Mekori, “Mast cells,” Physiological Reviews, vol. 77, no. 4, pp. 1033–1079, 1997. View at: Google Scholar
  42. J. S. Marshall, “Mast-cell responses to pathogens,” Nature Reviews Immunology, vol. 4, no. 10, pp. 787–799, 2004. View at: Publisher Site | Google Scholar
  43. J. S. Marshall, J. D. McCurdy, and T. Olynych, “Toll-like receptor-mediated activation of mast cells: implications for allergic disease?” International Archives of Allergy and Immunology, vol. 132, no. 2, pp. 87–97, 2003. View at: Publisher Site | Google Scholar
  44. S. J. Galli, S. Nakae, and M. Tsai, “Mast cells in the development of adaptive immune responses,” Nature Immunology, vol. 6, no. 2, pp. 135–142, 2005. View at: Publisher Site | Google Scholar
  45. R. Saluja, I. Delin, G. P. Nilsson, and M. Adner, “FcεR(1)-mediated mast cell reactivity is amplified through prolonged toll-like receptor-ligand treatment,” PLoS One, vol. 7, no. 8, Article ID e43547, 2012. View at: Google Scholar
  46. B. N. Melgert, D. S. Postma, M. Geerlings et al., “Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 6, pp. 880–885, 2004. View at: Publisher Site | Google Scholar

Copyright © 2013 M. E. Givi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2224 Views | 978 Downloads | 5 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.